Q-omics provides the consensus-scored NKX6-2 profile across patient tissues and cancer cell-line models. NKX6-2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NKX6-2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NKX6-2 RNA expression shows 13,400 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where NKX6-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX6-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX6-2 survival associations across molecular data types. NKX6-2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX6-2 RNA expression–survival associations across cancer types. High NKX6-2 expression shows unfavorable associations in BRCA, MESO, DLBC, THCA and ACC, but favorable associations in UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for NKX6-2 RNA expression.
This table summarizes NKX6-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NKX6-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX6-2 shows lower tumor expression in KIRC, KIRP, HNSC, KICH, THCA and STAD. The KIRC box plot shows higher NKX6-2 RNA expression in normal versus tumor tissue (log2 FC = −0.118, t-test p < 0.001).
This table shows molecular features associated with NKX6-2 in patient tissues and cancer cell lines. In patient samples, NKX6-2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX6-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
